Pfizer and J&J end development of Alzheimer's drug
August 6, 2012 in Alzheimer's disease & dementia
Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.
The companies say their drug bapineuzumab did not improve cognition or mental function in patients with mild to moderate Alzheimer's disease when compared to placebo. It was hoped that bapineuzumab would reduce the decline in physical and mental function for patients with Alzheimer's. Current treatments can only temporarily ease symptoms of the disease.
The two companies said July 23 that the drug had failed in a different trial. All other studies are being discontinued, and Johnson & Johnson said it will take a charge of $300 million to $400 million in the third quarter.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
-
Alzheimer's drug fails in 1 study, 2nd continues (Update)
Jul 23, 2012 |
not rated yet |
0
-
Study examines immunotherapy and cerebrospinal fluid biomarkers in patients with Alzheimer's disease
Apr 02, 2012 |
not rated yet |
0
-
Alzheimer's drug shows promise in early trial
Jul 18, 2012 |
not rated yet |
0
-
Eli Lilly halts development of Alzheimer's drug
Aug 17, 2010 |
not rated yet |
0
-
Neuroimaging technique shows potential of bapineuzumab treatment and might be useful in assessing other drugs for Alzhei
Feb 28, 2010 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How much negative charge do I accumulate by touching the earth?
1 hour ago
-
Indeterminism in Classical Physics
6 hours ago
-
Current in two wires
7 hours ago
-
understanding the dipole model for Rayleigh scattering
9 hours ago
-
question on coriolis effect with drag force
15 hours ago
-
Question of reflection and transmission of TEM wave in normal incidenc
20 hours ago
- More from Physics Forums - Classical Physics
More news stories
A new strategy required in the search for Alzheimer's drugs?
In the search for medication against Alzheimer's disease, scientists have focused – among other factors – on drugs that can break down Amyloid beta (A-beta). After all, it is the accumulation of A-beta that causes the ...
Alzheimer's disease & dementia
4 hours ago |
not rated yet |
0
Alzheimer's disease, the soft target of the euthanasia debate
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.
Alzheimer's disease & dementia
5 hours ago |
not rated yet |
0
Scientists discover cinnamon compounds' potential ability to prevent Alzheimer's
Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of –– or warding off ...
Alzheimer's disease & dementia
21 hours ago |
5 / 5 (5) |
0
|
Drug reverses Alzheimer's disease deficits in mice, research confirms
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.
Alzheimer's disease & dementia
23 hours ago |
not rated yet |
0
|
Multiple research teams unable to confirm high-profile Alzheimer's study
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Alzheimer's disease & dementia
23 hours ago |
3 / 5 (2) |
3
|
Storm chasers: born to be wild?
(HealthDay)—We've all seen them: the surfers who race to the beach when a hurricane hits, the guy who decides to ride out the storm in his overmatched boat, the tornado chasers who fearlessly steer their ...
Bulletin provides guidelines for second-trimester abortion
(HealthDay)—New evidence-based guidelines provide guidance on medical and surgical methods for second-trimester abortion and management of associated complications, according to a practice bulletin published ...
About one in four uninsured could be excluded from ACA
(HealthDay)—More than one in four of those eligible for new premium assistance tax credits under the Affordable Care Act (ACA) do not have a checking account and will not be able to receive premiums from ...
Modulating the immune system to combat metastatic cancer
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
New fluorescent tools for cancer diagnosis
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Top-ranked golfer beats scoliosis
(HealthDay)—As a world-class golfer, Stacy Lewis' accomplishments are remarkable. But it was a physical challenge in her childhood that defined her ascent to the top of her sport.
